On the heels of the $4.85 Billion Vioxx settlement, the Multi-District Litigation (MDL) Court for the Bextra/Celebrex litigation has set the first Bextra trial for May 5, 2008.
Following a review of safety information, Health Canada is informing the public that Bextra, an anti-inflammatory drug used to treat arthritis and pain, will not return to the market.
Bextra is a member of a class of drugs known as cox-2 inhibitors. Better known cox-2s are Celebrex, which is still sold, and Vioxx, which was pulled from worldwide markets in September 2004.
The FDA has decided not to approve a special formulation of Pfizer's recalled pain reliever Bextra that was to be used to treat pain following surgery.
The London-based European Medicines Agency said it would review the suspension of Bextra, which was first suspended in Europe and the United States in April, within one year.
Pfizer Inc. wants to put its second-generation COX-2 drug Bextra back on the market but lawyers for patients who contend they were harmed by the drug warn it was approved too hastily in the first place.
Pfizer Inc. Chief Executive Hank McKinnell says the companies Bextra anti-inflammatory drug will probably return to the market because of patient demand.
Pfizer's recent decision to withdraw Bextra at the FDA's request is drawing attorneys and medical experts to the New Orleans Ritz-Carlton on May 18 for an in-depth discussion of litigation involving the Cox-2 painkiller.
Pfizer's recent decision to withdraw Bextra at the FDA's request is drawing attorneys and medical experts to the New Orleans for an in-depth discussion of litigation involving the Cox-2 painkiller.
Beasley Allen law firm in Montgomery, Alabama believes that Pfizer's Bextra, another COX-2 inhibitor, posed a dual danger to thousands of consumers before its withdrawal last week.
